Dealing with diabetes: Carnitine palmitoyltransferases (CPT) are promising new targets for the treatment of diabetes. Here, derivatives of R‐aminocarnitine, with the quaternary ammonium moiety replaced by groups lacking a permanent cationic charge, were designed and evaluated in vitro and in vivo as L‐ CPT I inhibitors.
Tassoni E, Conti R, Gallo G, Vincenti S, Mastrofrancesco L, Brunetti T, et al. (2011). Derivatives of R-Aminocarnitine without Ammonium Moiety as Liver Carnitine Palmitoyltransferase I (L-CPT I) Inhibitors. CHEMMEDCHEM, 6(11), 1977-1980 [10.1002/cmdc.201100289].
Derivatives of R-Aminocarnitine without Ammonium Moiety as Liver Carnitine Palmitoyltransferase I (L-CPT I) Inhibitors
Cabri W;
2011
Abstract
Dealing with diabetes: Carnitine palmitoyltransferases (CPT) are promising new targets for the treatment of diabetes. Here, derivatives of R‐aminocarnitine, with the quaternary ammonium moiety replaced by groups lacking a permanent cationic charge, were designed and evaluated in vitro and in vivo as L‐ CPT I inhibitors.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
